RECRUITING

Prediction of Anxiety and Memory State

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to look at how signals in the brain, body, and behavior relate to anxiety and memory function. This project seeks to develop the CAMERA (Context-Aware Multimodal Ecological Research and Assessment) platform, a state-of-the-art open multimodal hardware/software system for measuring human brain-behavior relationships. The R61 portion of the project is designed to develop the CAMERA platform, which will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy, as well as to build CAMERA's passive data framework and active data framework.

Official Title

Developing the Context-Aware Multimodal Ecological Research and Assessment (CAMERA) Platform for Continuous Measurement and Prediction of Anxiety and Memory State

Quick Facts

Study Start:2024-07-23
Study Completion:2027-07-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06551090

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients must have known or suspected Temporal Lobe Epilepsy.
  2. * Native or proficient in speaking English or Spanish.
  3. * Stereoelectroencephalography (sEEG) cases: The implant plan must include hippocampal head, body, and tail electrodes either unilaterally or bilaterally.
  4. * 7th grade reading level (minimum level considered literate for adults)
  1. * Hearing impaired (i.e., not corrected with a hearing aid)
  2. * Unable to read the newspaper at arm's length with corrective lenses.
  3. * Objective intellectual impairment (estimated IQ \< 70)
  4. * Any history of Electroconvulsive Therapy or psychosis (except postictal psychosis for patients)
  5. * Psychotic disorder (lifetime)
  6. * Current Anxiety disorder, Major Depressive Disorder, or Bipolar Disorder
  7. * Neurodegenerative diseases, presence of widespread brain lesions, language problems (other than naming difficulty)
  8. * Medical conditions that could potentially affect cognitive performance (e.g., human immunodeficiency virus (HIV) infection, cancer with metastatic potential).
  9. * Acute renal failure or end-stage renal disease

Contacts and Locations

Study Contact

Brett Youngerman, MD
CONTACT
516-946-2145
bey2103@cumc.columbia.edu
Angela Velazquez
CONTACT
646-515-1909
agv2113@cumc.columbia.edu

Principal Investigator

Joshua Jacobs, PhD
PRINCIPAL_INVESTIGATOR
Columbia University

Study Locations (Sites)

Columbia University
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Columbia University

  • Joshua Jacobs, PhD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-23
Study Completion Date2027-07-22

Study Record Updates

Study Start Date2024-07-23
Study Completion Date2027-07-22

Terms related to this study

Additional Relevant MeSH Terms

  • Anxiety
  • Memory
  • Epilepsy